We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | 장 마감 후 (AMC) | — | — | — | $32.02M | — | 예정 |
| FY2014 Q3 | 2013. 02. 24. | 시각 미정 | — | $0.68 | — | — | $334.6M | 보고됨 |
| FY2014 Q2 | 2012. 11. 25. | 시각 미정 | — | $0.5 | — | — | $216.73M |
Consensus PT $6.67 · 3 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 04. 30. | Barrington Research | — | 의견 유지 | Outperform → Outperform | — | Barrington Research: Outperform |
| 2026. 03. 28. | Barrington Research | — | 의견 유지 | Outperform → Outperform | — | Barrington Research: Outperform |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2014 Q1 | 2012. 08. 26. | 시각 미정 | — | $0.17 | — | — | $102.07M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Stored first · Google News · Yahoo Finance (English)
Lifecore Biomedical (LFCR) Q1 2026 revenue drops but 2026 outlook reaffirmed - Stock Titan
Lifecore Biomedical (LFCR) Q1 2026 revenue drops but 2026 outlook reaffirmed Stock Titan
Lifecore (NASDAQ: LFCR) posts 34% revenue drop and high debt load - Stock Titan
Lifecore (NASDAQ: LFCR) posts 34% revenue drop and high debt load Stock Titan